BBNX (Beta Bionics) ROCE %: -33.53% (As of Mar. 2026)


BBNX Beta Bionics Inc BBNX
10 GF Score
Price $17.00
! 3 Warning Signs
View Full Analysis

What is Beta Bionics ROCE %?

Beta Bionics BBNX +1.71% 10 ROCE % is -33.53% as of Mar. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beta Bionics's annualized ROCE % for the quarter that ended in Mar. 2026 was -33.53%.

Beta Bionics  (NAS:BBNX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beta Bionics ROCE % Related Terms

Beta Bionics ROCE % Historical Data

* Premium members only.

The historical data trend for Beta Bionics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Bionics ROCE % Chart

Beta Bionics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
-242.88 -56.86 -39.71 -33.63

Beta Bionics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -33.14 -25.15 -22.16 -15.87 -33.53
BBNX
10GF Score
Beta Bionics Inc BBNX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics ROCE % Calculation

Beta Bionics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-71.681/( ( (149.645 - 21.148) + (328.743 - 30.924) )/ 2 )
=-71.681/( (128.497+297.819)/ 2 )
=-71.681/213.158
=-33.63 %

Beta Bionics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-97.084/( ( (328.743 - 30.924) + (304.417 - 23.191) )/ 2 )
=-97.084/( ( 297.819 + 281.226 )/ 2 )
=-97.084/289.5225
=-33.53 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -33.53% mean?
Beta Bionics (BBNX) has a ROCE % of -33.53% as of Mar. 2026.
Is Beta Bionics' ROCE % too high?
Beta Bionics' current ROCE % is -33.53%. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' ROCE % compare to CBLL and SIBN?
Beta Bionics' ROCE % of -33.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.19, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Bionics's current ROCE % is -33.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current ROCE % of -33.53%. The current ROCE % is -33.53%. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Beta Bionics (BBNX), the current ROCE % is -33.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score

Get the complete analysis for BBNX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.00
Price